Skip to main content

Table 1 Characteristics of the included studies

From: Efficacy and safety of mineralocorticoid receptor antagonists for patients with heart failure and diabetes mellitus: a systematic review and meta-analysis

Study Subjects (T/C) Age (T/C) Male (T/C) Ejection fraction, (%) (T/ C) Interventions (T/C) Follow-up period Outcomes Crude events (T/C)
O’Keefe (2007) [29] 749/734 66 ± 10/66 ± 10 63/64 32 ± 6 /32 ± 6 Eplerenone/Placebo Mean 16 months all-cause mortality 153/175
        Hyperkalaemia(>5.5 mmol/l) 42/22
        Death from CV causes 131/152
Eschalier (2013) [30] 459/400 68.1 ± 7.4/N.r. 356/N.r. 26.44 ± 4.7/N.r. Eplerenone/Placebo N.r Hyperkalaemia(>5.5 mmol/l) 63/33
        CV mortality+HF hospitalization 99/141
        Change in eGFR from baseline to final visit - 4.94(17.4)/-2.93(18.9)
Vadugana than (2014) [31] 444/306 65.1 ± 10.1/67.9 ± 10.7 320/242 26.7 ± 7.8/28.6 ± 8.8 MRAs/no MRAs Mean 9.9 months all-cause mortality; 101/98
        CV mortality+HF hospitalization 182/147
        Death from CV causes 78/66
Khosraviani (2014) [32] 536/1114 N.r. N.r. N.r. Spironolactone/no spironolactone 2 years all-cause mortality 79/223
  1. Notes: T Trial Group, C Control Group, N.r. not report, MRAs mineralocorticoid receptor antagonists, CV cardiovascular, HF heart failure, CI confidence interval, eGFR estimated glomerular filtration rate